RET Inhibitor Compounds Selective Kinase Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current RET inhibitors face challenges in effectively targeting both wild-type RET and its resistant mutants due to toxicity issues and the ability of tumor cells to develop resistance through kinase reactivation via mutation, limiting treatment options for cancers with RET fusions.
Innovation Solution
Development of specific compounds, such as those represented by Formulas (I), (II), and (III), which are designed to inhibit RET activity while minimizing toxicity by selectively targeting RET over other kinases, including resistant mutants, and are administered in pharmaceutical compositions to treat conditions mediated by aberrant RET activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If multi-kinase inhibitors with RET inhibitory activity are used to treat patients with RET fusion proteins, then RET activity is inhibited, but toxicities result from inhibition of targets other than RET
Solution Approach 1:
The patent applies local quality by designing compounds with specific molecular structures (Formulas I, II, III) that have differentiated binding characteristics. The compounds exhibit selective inhibition of RET over other kinases through specific structural features at positions R1-R8, achieving high RET selectivity ratio (IC50 KDR/RET ≥ 3-100×) to reduce off-target toxicities while maintaining RET inhibition efficacy
Solution Approach 2:
The patent utilizes parameter changes by systematically varying molecular parameters (substituents at R1-R8 positions, heteroatom configurations, stereochemistry) to optimize the balance between RET inhibition potency and selectivity. This structural parameter optimization enables achieving both high RET inhibition and reduced toxicity by adjusting molecular properties
2Reliability
If tumor cells become resistant to therapy through kinase reactivation via mutation, then treatment effectiveness decreases, but treatment options become limited
Solution Approach 1:
The patent applies universality by developing a series of compounds (Formulas I, II, III) that collectively target multiple RET variants including wild-type and resistant mutants (V804L, V804M, V804E, Y806H, G810R, L865V, L870F, S891A, M918T). The compound series provides broad-spectrum RET inhibition across different mutation types, maintaining therapy effectiveness despite resistance mutations and expanding treatment options
Solution Approach 2:
The patent applies dynamics by creating a flexible compound series with variable structural parameters that can adapt to different RET mutant configurations. The systematic variation in molecular structures (R1-R8 positions) allows the treatment approach to dynamically respond to different resistance mechanisms, maintaining effectiveness across evolving tumor populations
Data Source
AI summary
Described herein are compounds that inhibit wild-type RET and its resistant mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.